<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4860">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01902602</url>
  </required_header>
  <id_info>
    <org_study_id>HAB10-2012</org_study_id>
    <nct_id>NCT01902602</nct_id>
  </id_info>
  <brief_title>Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia</brief_title>
  <acronym>HAB</acronym>
  <official_title>Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herrmann Apparatebau GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herrmann Apparatebau GmbH</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the influence of the Great
      autohemotherapy with oxygen-ozone (hyperbaric ozone therapy ) to describe the cardiovascular
      system in patients with resistant hypertension. The primary endpoint is the change in mean
      blood pressure after 10 treatments .

      In addition, data are collected on the immune system as well as for food and sleep quality.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change of blood pressure</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary endpoint is, that there is a changing of the middle blood pressure after 10 treatments. The blood pressure will get messured at all patients which get treated with oxygen-ozone. The aim is reached, if there is a reduction of the middle blood pressure after 10 treatments by 10 mmHg compared to the blood pressure by the patients at the baseline at beginning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of pulse</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Pulse will be measured at each follow-up. It will be measured 3 times at the dominate arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood count, liver and nephrew values</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change of blood counts, liver and nephrew values serves as a sign for change of immune activity in a patient. Furthermore potential negative effects will be reportet as an adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of liver and nephrew values</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of life and Sleeping quality</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of life and sleeping quality will be measured in  a 7 scale. This questionnaire is to fill in by the patient.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertonia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients which fulfill the mentioned criterias.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Resistant Hypertension &gt; 140 / &gt; 90mmHg

          -  Inclusion age : 45 +

          -  Regular monitoring of blood levels considered

          -  pre-medication to lower blood pressure for at least 3 weeks before the preliminary
             investigation consistent

          -  Men and Women

        Exclusion Criteria:

          -  derailed diabetes

          -  renal impairment , renal creatinine clear &lt;50 ml

          -  Non - austherapierte cancer / tumor patients

          -  Non - adjusted thyroid dysfunction

          -  BMI&gt; 35

          -  LVEF &lt;limit ( &quot; 35% &quot; )

          -  Peripheral AVK ( ABI - measurement ) &gt; Stage II

          -  regurgitation &gt; Stage I

          -  abdominal aneurysm

          -  infections

          -  acute febrile infections with temperature &gt; 38.5 Â° C

          -  COPD and asthma to stage III

          -  dyspnea NYHA &gt; Stage III

          -  z.n. Stroke shorter than 12 weeks

          -  Acute liver failure

          -  Acute Apoplexy

          -  Severe poisoning

          -  drug addiction

          -  hyperthyroidism

          -  Hypotension

          -  hypocalcemia

          -  hypoglycemia

          -  ozone allergy

          -  pregnancy

          -  clotting problems ( hemophilia )

          -  pre-existing condition with hemoglobin &lt; 9mg/dl

          -  Fresh myocardial infarction

          -  Internal bleeding

          -  thrombocytopenia

          -  Acute alcohol

          -  Citrus allergy when using sodium citrate
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Panos Porikis, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>unafflicated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Panos Porikis</name>
      <address>
        <city>Biblis</city>
        <state>Hessen</state>
        <zip>68647</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Panos Porikis, Phd</last_name>
      <phone>+49 6245 8698</phone>
      <email>Dr.Porikis@t-online.de</email>
    </contact>
    <investigator>
      <last_name>Panos Porikis, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 12, 2013</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscle Hypertonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
